4.8 (325) In stock
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
新闻详情页-B. Braun Group
In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum
In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum
Apheresis Machines Market 2021: Comprehensive Study Explores
Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast
Digital Diabetes Management Market Size, Trends & Forecast
Digital Diabetes Management Market Size, Trends & Forecast
Apheresis Machines Market 2021: Comprehensive Study Explores
Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast
In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable
Digital Diabetes Management Market Size, Trends & Forecast
Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® - Cytosorbents
